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Compared to the standard arm, leukopenia  6 grade 3 was a 
rare event in the weekly arm of the D2 study (per-patient 
analysis: 4.2% q1w vs. 51.9% q3w; p  ! 0.0001). No difference 
was observed between the 2 schedules regarding the occur-
rence of anemia or thrombocytopenia. With regard to non-
hematological toxicity, there was a higher incidence of skin/
nail and hepatological toxicity with the weekly schedule, 
whereas neurotoxicity was observed more often in the stan-
dard arm. The rate of omitted doses was significantly in-
creased in the weekly arm (8.6% q1w vs. 0% q3w). The overall 
response rate was 22.9% in the weekly arm compared to 
42.6% in the standard arm (p = 0.039). Time to progression 
was 5.4 (q1w) versus 6.3 (q3w) months (p = 0.91), and overall 
survival was 22.7 (q1w) versus 15.8 (q3w) months (p = 0.24). 
 Conclusion: The present data support the feasibility of both 
weekly and 3-weekly application of docetaxel. As expected, 
severe leukopenia seems avoidable in weekly scheduled sin-
gle-agent docetaxel and may serve as an important treat-
ment option, particularly in elderly patients and patients 
with a reduced performance status. 
 Copyright © 2011 S. Karger AG, Basel 
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 Abstract 
 Purpose: Previous phase II studies have indicated a greatly 
reduced hematotoxicity of docetaxel-based regimens ad-
ministered on weekly schedules. The present trial was initi-
ated to randomly compare the toxicity and efficacy of week-
ly docetaxel versus its standard 3-weekly application.  Meth-
ods: Patients previously untreated with chemotherapy for 
metastatic disease were recruited. Patients aged  1 60 years 
or with a Karnofsky Perfomance Status (KPS) of 60–80% were 
eligible for the D2 study. Patients were randomized to re-
ceive docetaxel either on a 3-weekly [75 mg/m 2 every 3 
weeks (q3w)] or on a weekly (30 mg/m 2 on days 1, 8, and 15; 
q4w) schedule. Treatment was continued until a maximum 
of 8 cycles, unacceptable toxicity, or disease progression. All 
patients received standard corticosteroid prophylaxis.  Re-
sults: Since statistical significance for the primary endpoint 
(toxicity) was achieved in the interim analysis, the study was 
closed according to the study protocol (102 of 162 patients). 
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 Introduction 
 Docetaxel (Taxotere; Sanofi-Aventis, Frankfurt, Ger-
many) is one of the most effective antitumor agents cur-
rently available for the treatment of breast cancer. In ear-
ly breast cancer, it is currently considered a standard op-
tion in node-positive and high-risk node-negative disease. 
In metastatic breast cancer (MBC), when compared to 
doxorubicin, docetaxel showed a significantly superior 
response rate (RR; 47.8 vs. 33.3%; p = 0.008) and a trend 
towards a prolonged time to progression (TTP; 26 vs. 21 
weeks)  [1] . After failure with anthracycline-containing 
chemotherapy, single-agent docetaxel has demonstrated 
superior results when compared to mitomycin/vinblas-
tine [RR, TTP, and overall survival (OS)] or methotrex-
ate/5-fluorouracil (RR and TTP). Moreover, it has shown 
equivalent efficacy when compared to vinorelbine/5-flu-
orouracil (RR, TTP, and OS)  [2–4] .
 When docetaxel is administered at a standard dose of 
100 mg/m 2 [every 3 weeks (q3w)], 70–90% of patients de-
velop grade 3/4 neutropenia  [1] . Instead of dose reduction, 
one strategy to reduce toxicity without growth factor sup-
port is to apply docetaxel on a weekly schedule. Several 
studies have indicated that severe hematotoxicity (grade 
3/4) could largely be prevented at weekly doses of less 
than 40 mg/m 2 without impaired efficacy in the first- or 
second-line setting  [5–9] . Meanwhile, the favorable toxic-
ity profile of weekly scheduled docetaxel has been con-
firmed in 2 randomized phase III trials without inferior 
results regarding TTP or OS  [10, 11] . A further rationale 
for weekly docetaxel might be that standard-dose single-
agent docetaxel (100 mg/m 2 q3w) frequently needs to be 
adjusted to 75 mg/m 2 in pretreated, unfit, or elderly pa-
tients  [12] . 
 Taken together, this evidence provided the basis to 
conduct the D2 trial which investigated a dose-adjusted 
3-weekly regimen (75 mg/m 2 ) compared to a weekly reg-
imen (30 mg/m 2 ) in elderly or medically unfit patients. 
 Patients and Methods 
 Patient Selection 
 Patients with MBC were recruited for the trial. None of the 
patients had received chemotherapy for metastatic disease. The 
treatment protocol was approved by the local ethics committees 
and all patients gave their written informed consent before treat-
ment was started. 
 For the D2 study, patients (aged  6 18 years) were required to 
have a Karnofsky Performance Status (KPS) of 60–80% or an age 
 6 60 years. Moreover, patients were required to have histologi-
cally proven MBC, bidimensionally measurable disease, and an 
anticipated survival of at least 12 weeks. Prior to study entry, he-
patic, renal, and hematological functions had to be adequate [leu-
kocyte count  6 3.0  ! 10 9 /l, platelets  6 100  ! 10 9 /l, hemoglobin 
 6 8 g/dl, bilirubin  ^  1.25 times the normal range, alanine ami-
notransferase:aspartate aminotransferase (ATL:AST) ratio  ^  3 
times the normal range, and alkaline phosphatase  ^  2.5 times the 
normal range].
 Patients with bone metastases only and/or steroid (estrogen 
and/or progesterone) receptor expression without prior endo-
crine treatment were not eligible for the trial. Additional exclu-
sion criteria were active infections, previous or concurrent radio-
therapy of more than 25% of marrow-containing bone, clinically 
overt brain metastases, previous neuropathy  6 grade II, and a his-
tory of a second malignancy other than resected basal cell and/or 
squamous cell carcinoma of the skin. Patients were not eligible for 
study enrolment if they were pregnant or lactating or if they re-
fused effective contraception.
 Treatment Regimen 
 Patients were randomly assigned to receive docetaxel either on 
a 3-weekly (75 mg/m 2 q3w) or weekly schedule (30 mg/m 2 days 1, 
8, and 15; q4w). Docetaxel was dissolved in 100 ml of 0.9% saline 
and given by intravenous (i.v.) infusion over 30 min (30 mg/m 2 
weekly) or 60 min (75 mg/m 2 q3w), respectively. Treatment was 
continued until a maximum of 8 cycles, unacceptable toxicity,
or disease progression. All patients received standard corticoste-
roid prophylaxis, antiemetics (routinely 5HT3 antagonists), and 
growth factors (which were allowed at any point) according to the 
local standards. 
 In case of myelosuppression on the day of the planned treat-
ment (leukocytes  ^  1,000/  l and platelets  ^  50,000/  l), further 
drug administration was postponed for 1 week until bone mar-
row recovery occurred (leukocytes  6 2,000/  l and platelets 
 6 100,000/  l). If there was no recovery within the additional rest 
of 1 week, the patient was excluded from the study. A reduced dose 
(–25%) was applied in case of a leukocyte count between 1,000/
  l and 2,000/  l and a platelet count between  6 50,000/  l
and 100,000/  l. A full dose of docetaxel was administered if the 
blood counts had risen to leukocytes  6 2,000/  l and platelets 
 6 100,000/  l.
 Patients were excluded from the trial in case of nonhemato-
logical toxicity  6 grade 3 (excluding nausea/vomiting). Dose re-
ductions of 25% were required in case of hematological toxicity 
grade 3 or 4 complicated by fever, infection, or both. Moreover, a 
reduced dose (–20%) was required in case of grade 3 diarrhea or 
mucositis. 
 Data Collection 
 Drug administration, KPS, and toxicity or adverse events were 
recorded after every cycle of treatment. Weekly blood counts were 
performed. Febrile neutropenia was defined as fever ( 6 38   °   C) 
with grade 4 neutropenia requiring i.v. antibiotics and/or hospi-
talization without documented infection. Fluid retention includ-
ed peripheral edema and/or pleural and pericardial effusions. 
 Toxicity was graded according to the National Cancer Insti-
tute’s Common Toxicity Criteria (NCI CTC 2.0)  [13] . Imaging 
studies using ultrasonography, computed tomography (CT), and 
magnetic resonance imaging (MRI) were performed after every 2 
cycles of treatment. 
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 Response Evaluation 
 In all patients, tumors were measured by imaging procedures 
(ultrasound, CT, or MRI) within 14 days prior to entry into the 
study and subsequently after every 2 cycles of treatment. A stan-
dard evaluation comprised of history, a physical examination, and 
routine laboratory tests (including a complete blood cell count, 
chemistry profile, and electrolyte determination) was performed 
before each treatment. 
 Patient response was assessed according to standard WHO 
criteria as follows: Complete response (CR) was defined as the 
disappearance of all known disease as determined by 2 observa-
tions not less than 4 weeks apart, while partial response (PR) was 
defined as a decrease of at least 50% in the sum of the products of 
the largest perpendicular diameters of all measurable lesions as 
determined by 2 observations not less than 4 weeks apart. Stable 
disease (SD), lasting at least 6 weeks from the start of study (i.e. 
the first drug administration), was defined as a  ! 50% decrease 
and a  ! 25% increase in the sum of the products of the largest per-
pendicular diameters of all measurable lesions. Progressive dis-
ease (PD) was a  1 25% increase in the size of at least 1 bidimen-
sionally or unidimensionally measurable lesion or the appearance 
of a new lesion. The occurrence of pleural effusion was considered 
a sign of progression if it was verified by positive cytology. 
 Study Endpoints and Statistics 
 The primary study endpoint was hematotoxicity (leukopenia). 
Assuming grade 3 and grade 4 hematotoxicity rates of 70–95% for 
the standard regimen and 10–20% for the weekly regimen, the 
calculated sample size for the primary endpoint was 40 patients 
(20 for each treatment arm), with a statistical power of 80% using 
a 5% level of significance (Fishers’s exact test). 
 An interim analysis was planned in 80 recruited patients (40 
for each treatment arm) for the primary endpoint using   1 = 
0.0052 and   2 = 0.048 as the levels of significance (O’Brien and 
Fleming sequential design).
 The calculated sample size for the secondary endpoint (TTP) 
was 162 patients, with the assumption of the noninferiority of the 
weekly schedule (TTP q3w = 7 months and TTP q1w = 6.5 
months). Sample sizes were calculated using NCSS/PASS 2000 
software. Further secondary endpoints were OS and RR. TTP was 
determined by the interval between the initiation of therapy and 
the first date that disease progression was objectively document-
ed. OS was measured from the date of the start of treatment to the 
date of death from any cause. All patients were included in the 
(intent-to-treat) analysis of TTP and survival. 
 The probabilities of survival and TTP were estimated by
Kaplan-Meier analysis, and confidence intervals for the RR were 
calculated using methods for exact binominal confidence inter-
vals  [14, 15] . 
 Results 
 Patient Characteristics  
 Patients were recruited between July 2001 and August 
2008. Since statistical significance was achieved for the 
primary endpoint in the interim analysis, the study was 
closed before the target recruitment had been reached 
(102 of 162 patients). The median observation time was 
14.4 months (range 1.2–77.7). The patients’ characteris-
tics are presented in  table 1 . 
 Toxicity 
 All investigated hematological and nonhematological 
toxicities are listed in  table 2 . Compared to the standard 
arm, leukopenia  6 grade 3 was a rare event in the weekly 
arm of the D2 study (per-patient analysis: 4.2% q1w vs. 
51.9% q3w; p  ! 0.0001). There was no difference regard-
ing the occurrence of anemia or thrombocytopenia be-
tween the 2 schedules.
 With regard to nonhematological toxicity, neurotoxic-
ity was observed more frequently in the standard regimen 
(3.7% q3w vs. 0% q1w; p = 0.01), whereas skin and nail dis-
Table 1.  Patient characteristics
Characteristics D 2 (n = 102)
q1 w q3w
Patients 48 54
Age, years
Median
Range
73
58–84
70.5
60–82
KPS, %
Median
Range
80
60–100
80
60–100
Estrogen and progesterone receptor status
Positive
Negative
Unknown
36
12
0
35
17
2
Menopausal status
Premenopausal
Postmenopausal
0
48
0
54
HER-2 status
Positive (IHC 3+ or 2+ and FISH+)
Negative (IHC 0 or 1+ or 2+ and FISH–)
Unknown
6
30
12
6
36
12
Measurable disease sites
Lung
Liver
Lymph nodes
Skin
Skeleton
23
23
23
8
20
23
27
23
6
24
Disease sites per patient, n
   1
   2
≥3
11
15
22
15
14
25
Prior treatment
Adjuvant chemotherapy
(including anthracyclines)
Adjuvant hormonal therapy
19
10
31
24
16
35
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orders were observed more often in patients who received 
weekly scheduled docetaxel (5.6% q3w vs. 14.6% q1w; p = 
0.03). Moreover, increased values for AP and GGT were 
measured significantly more often in the weekly arm.
 The median number of applied cycles was 6 (range 1–8) 
for the standard arm and 4 (range 1–8) for the weekly arm. 
The median duration of treatment was 105 days (range 
5–181) for the standard arm and 97.5 days (range 1–210) 
for the weekly schedule. There were no significant differ-
ences regarding dose reductions, delayed doses, or the 
percentage of the intended drug delivered within a cycle 
between the 2 regimens (standard vs. weekly dose). Solely, 
the rate of omitted doses within the cycle (days 1, 8, and 
15) was significantly increased in the weekly arm (8.6% 
q1w vs. 0% q3w). These data are summarized in  table 3 . 
 Efficacy 
 In an intent-to-treat analysis, 1 CR, 33 PR, 36 SD, and 
20 PD were observed. Twelve patients were not evaluable. 
The overall RR was 33.3% (95% CI 24.3–43.4). The RR in 
the group of standard docetaxel q3w was approximately 
twice as high as that of the weekly group (42.6% q3w vs. 
22.9% q1w; p = 0.039). Nevertheless, the significantly 
higher response rate did not result in a significantly im-
proved TTP (5.4 months q1w vs. 6.3 months q3w; p = 0.91) 
or OS (22.7 months q1w vs. 15.8 months q3w; p = 0.24) 
( fig. 1 ). The response and survival data are presented in 
 tables 4 and  5 and in  figure 1 . 
Table 2.  Toxicity profile (per-patient analysis): hematological and nonhematological toxicity by NCI CTC grade
A (q3w), % B (q1w), % p value (after 
dichotomiza-
tion ≤2/≥3)0 1 2 3 4 0 1 2 3 4
Hematological toxicity
Anemia 18.5 51.8 25.9 3.7 0 27.1 43.8 29.2 0 0 >0.05
Leukopenia 22.2 9.3 16.7 35.2 16.7 43.8 31.4 20.7 4.1 0 <0.0001
Thrombocytopenia 87.0 11.1 0 1.9 0 81.3 18.7 0 0 0 >0.05
Nonhematological toxicity
Alopecia 20.3 9.2 70.5 0 0 29.2 12.5 58.3 0 0 >0.05
AP 66.7 27.8 5.6 0 0 60.4 27.1 6.3 6.3 0 0.02
Arrhythmias 94.4 3.7 1.9 0 0 93.8 0 4.2 0 2.1 >0.05
Bilirubin 96.3 1.8 1.9 0 0 83.3 6.3 6.3 4.2 0 >0.05
Constipation 74.1 16.7 9.3 0 0 81.3 10.4 4.2 4.2 0 >0.05
Creatinine 77.8 18.5 1.9 1.9 0 79.2 14.6 6.3 0 0 >0.05
Diarrhea 62.9 14.8 11.1 11.1 0 54.2 25.0 12.5 8.3 0 >0.05
Fever 79.6 5.6 5.6 7.4 1.9 87.5 6.3 4.2 2.1 0 >0.05
Fluid retention 72.2 22.2 3.7 1.9 0 81.3 4.2 12.5 2.1 0 >0.05
Gastrointestinal symptoms 90.7 5.6 1.9 1.9 0 100.0 0 0 0 0 >0.05
GGT 38.9 29.6 18.5 12.9 0 39.6 20.8 20.8 10.4 8.3 0.01
Infections 77.8 12.9 1.9 7.4 0 75.0 8.3 10.4 6.3 0 >0.05
Mucositis 64.8 14.8 12.9 7.4 0 64.6 20.8 8.3 4.2 2.1 >0.05
Musculoskeletal disorders 98.1 0 1.9 0 0 93.8 4.2 2.1 0 0 >0.05
Nausea and vomiting 48.2 29.6 14.8 7.4 0 52.1 33.3 10.4 4.2 0 >0.05
Neurotoxicity 59.3 25.9 11.1 3.7 0 54.2 31.3 14.6 0 0 0.01
Edema 79.6 12.9 3.7 1.9 1.9 89.6 4.2 4.2 0 2.1 >0.05
Pain 48.2 24.1 24.1 3.7 0 54.2 14.6 29.2 0 2.1 >0.05
Skin and nail disorders 59.3 12.9 22.2 5.6 0 70.8 8.3 6.3 14.6 0 0.03
Table 3.  Toxicity profile: dose modifications
All
(n = 481)
q3w
(n = 295)
q1w
(n = 186)
p
value
Cycles
Dose reductionsa 48 (9.98) 26 (8.81) 22 (11.83) >0.05
Delayed dosesa 45 (9.36) 23 (7.80) 22 (11.83) >0.05
Omitted dosesa 16 (3.33) 0 16 (8.60) <0.001
Percentage of intended
drug delivery 94.6 95.7 92.8 >0.05
a  Reductions within a cycle; data given as n (%).
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 Discussion 
 Numerous phase II studies have shown a considerably 
reduced hematotoxicity of weekly scheduled docetaxel 
with stable efficacy in the first- or second-line setting of 
MBC  [5–9] . These data led to the initiation of the ran-
domized D2 study in July 2001 which compared a dose-
adjusted 3-weekly regimen (75 mg/m 2 ) to a weekly regi-
men (30 mg/m 2 ) in elderly or medically unfit patients in 
first-line MBC. 
 As expected, leukopenia  6 grade 3 was rarely seen in 
the weekly arm of the D2 study (per-patient analysis: 
4.2% q1w vs. 51.9% q3w; p  ! 0.0001). Due to the high sig-
nificance of this finding, the study was stopped accord-
ing to the study protocol after an interim analysis (the 
primary endpoint was toxicity, i.e. ‘leukopenia’; recruited 
patients: 102 of 162 patients).
 Skin and nail disorders are known sequelae of docetax-
el  [7, 16] . The frequency of these side effects ( 6 grade 3) 
was significantly increased in patients who were random-
ized to the weekly arm (14.6% q1w vs. 5.6% q3w; p = 0.03), 
whereas the rate of neurotoxicity  6 grade 3 was increased 
in the 3-weekly arm (3.7% q3w vs. 0% q1w; p = 0.01). Al-
though these side effects can be a dose-limiting factor 
even in elderly patients, they did not result in a shorter 
treatment duration in the weekly arm (105 days q3w vs. 
97.5 days q1w). Clinically irrelevant but significant chang-
es in AP and GGT were observed more frequently in pa-
tients who received weekly scheduled docetaxel. 
Table 4.  Efficacy: RR (intent-to-treat analysis)
D2 CR PR SD PD Not evaluable RR, % 95% CI, % p
All patients (n = 102) 1 33 36 20 12 33.3 24.3–43.4
q1w group (n = 48) 0 11 18 12 7 22.9 12.0–37.3 0.039aq3w group (n = 54) 1 22 18 8 5 42.6 29.2–56.8
a  RR q1w versus q3w.
Table 5.  Efficacy: TTP and OS
D2 q3w q 1w p value
(log-rank
test)median range median range
TTP, months 6.3 0.4–20.1 5.4 0.7–48.2 >0.05
OS, months 15.8 1.2–32.8 22.7 1.8–41.4 >0.05
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
0 180 360 540 720 900 1,080 1,260 1,440 1,620
D2: median OS
q3w 15.8 mo
q1w 22.7 mo
p = 0.24
D2: median TTP
q3w 6.3 mo
q1w 5.4 mo
p = 0.91
Pr
op
or
tio
n 
of
 s
ur
vi
va
l
Time (days)
 Fig. 1. TTP and OS for the q3w group ver-
sus the q1w group. mo = Months. 
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 Despite a significantly lower hematotoxicity, the rate 
of omitted doses within a cycle significantly increased in 
patients who received weekly docetaxel (8.6% q1w vs. 0% 
q3w; p = 0.001). Except for an increased rate of skin and 
nail toxicity, we cannot provide any other reasonable ex-
planation for this finding. 
 With regard to efficacy, the RR was inferior in the 
weekly arm compared to the standard regimen (22.9% 
q1w vs. 42.6% q3w; p = 0.039). Nevertheless, the almost 
doubled RR in the 3-weekly regimen did not result in any 
improvement regarding TTP or OS. TTP was 5.4 (q1w) 
versus 6.3 (q3w) months (p = 0.91), and OS was 22.7 (q1w) 
versus 15.8 (q3w) months, respectively (p = 0.24). 
 A conclusive statement regarding efficacy is restricted 
by the fact that the calculated sample size for the second-
ary efficacy endpoints (TTP and OS) was not reached in 
the D2 study because the study was terminated prema-
turely after reaching statistical significance for its prima-
ry endpoint in the interim analysis. 
 However, the present data confirmed the favorable 
and different toxicity profile of weekly scheduled docetax-
el, without any suggestion of inferior results regarding 
TTP or OS. These data have basically been confirmed in 
2 randomized phase III trials by Rivera et al.  [10] and Ta-
bernero et al.  [11] . Patients who received docetaxel q3w in 
the study of Rivera et al.  [10] experienced a more pro-
nounced toxicity. Despite an inferior RR for the weekly 
schedule (20.3% q1w vs. 35.6% q3w), patients experienced 
similar PFS (5.5 q1w vs. 5.7 q3w months; p = 0.46) and OS 
(18.6 q1w vs. 18.3 q3w months; p = 0.34). 
 The rather low rate of severe leukopenia associated 
with weekly docetaxel may permit its combination with 
an anthracycline. Both agents are considered among the 
most active single agents for the treatment of early and 
MBC. Consequently, their combined use is a logical step 
in the search for highly effective chemotherapy combina-
tions. Numerous phase II trials have investigated a 3-week 
scheduled anthracycline/taxane regimen with impres-
sively high response rates of 46–88%  [17–20] . However, 
the dose-limiting factor in these trials has been leukope-
nia, leading to the initiation of phase II trials investigat-
ing weekly anthracycline/taxane combinations. Such 
studies have shown proven efficacy with a manageable 
toxicity profile  [21, 22] . Gamucci et al.  [21] reported a con-
siderably low rate of  6 grade 3 neutropenia of 16% of
patients who received first-line weekly epirubicin (25
mg/m 2 ) and docetaxel (25 mg/m 2 ) for MBC  [21] . The reg-
imen was quite effective with a response rate of 60% and 
a median OS of 25 months. Moreover, Perez-Manga et al. 
 [22] reported on a phase II study which investigated a 
combination of doxorubicin (50 mg/m 2 q4w) and weekly 
docetaxel (36 mg/m 2 days 1, 8, and 15; q4w) for locally 
advanced or metastatic breast cancer (first line)  [22] . A 
consistently low rate of severe neutropenia ( 6 grade 3) 
was reported (7%, with 4% febrile neutropenia) and the 
RR were considerably high, i.e. 93 and 64%, among the 
locally advanced metastasized patients, respectively.
 In conclusion, the results of the D2 study have con-
firmed the favorable toxicity profile of weekly docetaxel. 
Regarding efficacy, our study indicated equivalence in 
terms of TTP and OS. Nevertheless, these data need to be 
taken with caution due to the premature closure of the 
trial after reaching statistical significance for the primary 
endpoint in the interim analysis. The weekly regimen re-
mains a valuable approach in elderly, unfit, or pretreated 
patients. Since phase II data indicated a greatly reduced 
hematotoxicity with weekly scheduled docetaxel/anthra-
cycline combinations, a randomized phase III study (D4) 
has already been conducted to further evaluate this ap-
proach.
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